[FG] Wild Damian

The main research interests are the development and clinical translation of novel diagnostic and therapeutic radiotracers in the field of oncology including neuroendocrine tumors.

Research Focus

Oncology & Hematology

Area of Research

Development, clinical transfer and evaluation of radiotracers for molecular Imaging and cancer therapy.

Approved Research Projects

• 2018 "177Lu-PP-F11N phase I study”, Grant from Debiopharm as part of a License Agreement between Debiopharm and Paul Scherrer Institute and Agreement between Paul Scherrer Institute and University Hospital Basel
• 2021 "xSPECT-based myocardial perfusion scintigraphy: consistency of functional values and feasibility of myocardial uptake quantitation in patients with suspected or known coronary artery disease – pilot study”, Grant form Siemens for collaboration project 40
• 2021 "Comparison of a new high-resolution collimator with standard collimator technique in quantitative 99mTc-DPD SPECT/CT for the diagnosis of prosthetic loosening. Analysis of model specific uptake distribution around joint prosthesis in quantitative SPECT data using voxel-based morphometry”, Grant form Siemens for collaboration project 41
• 2022 "Combined beta- and Auger electron therapy using a novel somatostatin receptor subtype 2 antagonist labelled with terbium-161 (161Tb-DOTA-LM3) – a phase 0/ phase I study”, Swiss National Science Foundation (SNF Grant Number 32003B_205070)
• 2023 Targeted radionuclide therapy in metastatic prostate cancer using a new PSMA ligand radiolabelled with terbium-161 (161Tb-SibuDAB) - dose identification/escalation Phase Ia/b study
• 2024 61 Cu-NODAGA-LM3 PET /CT for the Detection of Neuroendocrine Tumors: The COPPER PET in NET Study A prospective, open-label, randomized, controlled, single centre, phase 1/11 PET /CT study

Collaborations

National Collaborations

• Close collaboration with Paul Scherrer Institut (PSI), Center for Radiopharmaceutical Sciences, Villigen, Prof. Roger Schibli, Dr. Martin Béhé, Dr. Cristina Müller, Dr. Nicolas van der Meulen: 177Lu-PP-F11N, 161Tb-DOTA-LM3, 161Tb-PSMA
• Nuclidium AG, Basel, Dr. Leila Jaafar-Thiel: 61Cu-NODAGA-LM3, 61Cu-NODAGA-PSMA

International Collaborations

• Sahlgrenska University, Gothenburg, Sweden, Prof. Peter Bernhard, 161Tb dosimetry
• Siemens Healthineers, Hoffman Estates, Chicago, USA, Dr. Hans Vija: xSPECT
• Itm, Munich, Germany, Dr. Konstatin Zhernosekov: 177Lu-ITG-PSMA-1
• Technical University of Munich, Prof. Wolfgang A. Weber: 61Cu-NODAGA-LM3

Ongoing Research Projects

Ongoing investigator initiated projects with own compounds (USB owns at least ¼ of IP):

• In this 2015 approved Debiopharm sponsored study (177Lu-PP-F11N medullary thyroid cancer and neuroendocrine tumor project; prospective single center clinical phase I study, ClinicalTrial.gov: NCT02088645) I act as the primary applicant and co-investigator. Based on this study we plan an application for a “temporary license” for using 177Lu-PP-F11N outside of clinical trials as salvage therapy (according to TPA Art. 9b). Collaboration with Paul Scherrer Institut.
• In this 2021 approved Swiss National Science Foundation application (161Tb-DOTA-LM3 neuroendocrine tumor project; prospective single center clinical phase 0/I study, SNF 32003B_205070, ClinicalTrial.gov: NCT0539146).

Ongoing investigator initiated projects:

• In this 2021 approved Swiss Hadron Foundation and Swiss Society of Nuclear Medicine sponsored study (177Lu-ITG-PSMA-1 prostate cancer project; multicenter, national registry-based, clinical observational study).
• In this 2021 approved Siemens sponsored study (xSPECT-based quantification of myocardial perfusion imaging; prospective single center clinical imaging study).
• In this 2021 approved Siemens sponsored study (xSPECT-based identification of prosthetic loosening; prospective single center clinical imaging study).